Skip to main content
. Author manuscript; available in PMC: 2010 Feb 15.
Published in final edited form as: Clin Cancer Res. 2009 Feb 15;15(4):1411–1416. doi: 10.1158/1078-0432.CCR-08-1141

Figure 2.

Figure 2

A) Kaplan-Meier curves for the development of HFSR toxicity with single agent sorafenib (°) versus combination therapy (*), p=0.0008. Median dose of sorafenib to noted HFSR toxicity for combination therapy was 21,117 mg versus not reached for single agent. B) Kaplan-Meier curves for the development of rash with single agent sorafenib (°) versus combination therapy (*), p=0.99. Median dose of sorafenib to noted rash for combination therapy was 26,870 mg versus 31000 mg for single agent.